Appeal No. 2001-1685
Application No. 08/596,698
1. A method of reducing amounts of intraocular fibrin comprising the
administration of a pharmacologically effective dose of Protein C so as to reduce the
amount of intraocular fibrin in an individual having elevated levels of intraocular fibrin.
9. A method of inhibiting intraocular fibrin formation comprising the
administration of a pharmacologically effective dose of Protein C so as to reduce the
amount of intraocular fibrin in an individual at risk for development of elevated levels of
intraocular fibrin.
The references relied upon by the examiner are:
Bang et al. (Bang) 5,151,268 Sept. 29, 1992
Stocker et al. (Stocker) 4,849,403 July 18, 1989
Iverson et al. (Iverson), “Inhibition of Intraocular Fibrin Formation Following Infusion of
Low-Molecular Weight Heparin During Vitrectomy,” Arch. Ophthamol., Vol. 109. pp.
405-409 (1991)
The references relied upon by the appellants are:
Howard et al. (Howard), “Intraocular Tissue Plasminogen Activator in a Rabbit Model of
Traumatic Hyphema,” Arch. Ophthalmol., Vol. 109, pp. 272-274 (1991)
Snyder et al. (Snyder), “Intraocular Fibrinolysis With Recombinant Human Tissue
Plasminogen Activator,” Arch. Ophthalmol., Vol. 105, pp. 1277-1280 (1987)
Grounds of Rejection
Claims 1-21 stand rejected under 35 U.S.C. § 103(a) as obvious over Iverson in
view of Bang.
Claims 7-8 and 20-21 stand rejected under 35 U.S.C. § 103(a) as obvious over
Iverson in view of Bang in further view of Stocker.
We reverse.
2
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007